157717-58-3

Usage

Uses

Used in Medicinal Chemistry:
(S)-3-AZIDO-4,4-DIMETHYLDIHYDROFURAN-2(3H)-ONE is used as a key intermediate in the synthesis of various organic molecules for medicinal chemistry applications. Its unique structure and azido group make it a valuable building block for the development of new pharmaceutical compounds.
Used in Materials Science:
In the field of materials science, (S)-3-AZIDO-4,4-DIMETHYLDIHYDROFURAN-2(3H)-ONE is used as a component in the synthesis of advanced materials. Its azido group allows for click chemistry reactions, which are widely used in the development of new materials with specific properties.
Used in Bioconjugation:
(S)-3-AZIDO-4,4-DIMETHYLDIHYDROFURAN-2(3H)-ONE is used as a bioconjugation agent due to its compatibility with click chemistry reactions. This allows for the efficient and specific attachment of biological molecules to various surfaces or other molecules, which is crucial in the development of biosensors, drug delivery systems, and other bio-related applications.

Upstream product

• 157717-57-2 (3R)-4,4-dimethyl-2-oxotetrahydrofuran-3-yl trifluoromethanesulfonate 
• 599-04-2 (R)-Pantolacton 

Downstream Products

• 1026967-98-5 (S)-2-((S)-2-Azido-4-hydroxy-3,3-dimethyl-butyrylamino)-3-phenyl-propionic acid tert-butyl ester 
• 858034-62-5 (S)-benzyl 2-(tert-butoxycarbonylamino)-4-hydroxy-3 ,3-dimethylbutanoate 
• 1026864-32-3 (E)-(S)-4-[(S)-2-((S)-2-Benzyloxycarbonylamino-4-hydroxy-3,3-dimethyl-butyrylamino)-3-phenyl-propionylamino]-6-(trityl-carbamoyl)-hex-2-enoic acid ethyl ester 
• 1025872-62-1 (S)-2-((S)-2-Benzyloxycarbonylamino-4-hydroxy-3,3-dimethyl-butyrylamino)-3-phenyl-propionic acid 

Relevant academic research and scientific papers

Use of R-pantolactone in the synthesis of L-tert leucine derivatives

A 4 step synthesis of the N-Boc-β,β-Dimethyl Homoserine lactone from inexpensive, commercially available R-Pantolactone is described.

CHEMICAL COMPOUNDS AS H-PGDS INHIBITORS

A compound of formula (I) wherein R1, R2, R3, R4, X, Y, and A are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne muscular dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Structure-activity relationship of daptomycin analogues with substitution at (2S, 3R) 3-methyl glutamic acid position

Daptomycin is a highly effective lipopeptide antibiotic against Gram-positive pathogens. The presence of (2S, 3R) 3-methyl glutamic acid (mGlu) in daptomycin has been found to be important to the antibacterial activity. However the role of (2S, 3R) mGlu i

Mechanism-Guided Development of a Highly Active Bis-thiourea Catalyst for Anion-Abstraction Catalysis

We describe the rational design of a linked, bis-thiourea catalyst with enhanced activity relative to monomeric analogues in a representative enantioselective anion-abstraction reaction. Mechanistic insights guide development of this linking strategy to f

Hepatitis C Virus Inhibitors

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

Hepatitis C Virus Inhibitors

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.